Table 1.
Patient, tumor, and treatment characteristics.
| n=52 | |
|---|---|
| Age (years) | |
| Mean | 71 |
| Median (range) | 72 (49-88) |
| Race | |
| Caucasian | 32 (61.5%) |
| African American | 14 (26.9%) |
| Other | 6 (11.5%) |
| BMI (kg/m2) | |
| <18.5 | 0 (0%) |
| 18.5-24.9 | 12 (23.1%) |
| 25-29.9 | 25 (48.1%) |
| 30-34.9 | 8 (15.4%) |
| 35-39.9 | 5 (9.6%) |
| 40-44.9 | 2 (3.8%) |
| Pretreatment PSA (ng/ml) | |
| Mean | 9.1 |
| Median | 8.1 (3.6-39.3) |
| Gleason Score | |
| 6 (3 + 3) | 4 (7.7%) |
| 7 (3 + 4) | 13 (25.0%) |
| 7 (4 + 3) | 28 (53.8%) |
| 8 (4 + 4), 9 (4 + 5) | 7 (13.5%) |
| Risk Group | |
| Intermediate - Favorable | 12 (23.1%) |
| Intermediate - Unfavorable | 32 (61.5%) |
| High | 8 (15.4%) |
| Prostate volume (cc) | |
| Mean | 43.1 |
| Median | 40 (15-124) |
| % of total cores involved | |
| Mean | 43.6 |
| Median | 38.0 (7.7-100) |
| Maximum % of a single involved core | |
| Mean | 57.0 |
| Median | 60 (5-95) |
| SBRT Dose (Gy) | |
| 36.25 | 48 (92.3%) |
| 40, 36.25 | 4 (7.7%) |